Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
243.47
-4.06 (-1.64%)
At close: Jul 20, 2026, 4:00 PM EDT
243.01
-0.46 (-0.19%)
Pre-market: Jul 21, 2026, 4:37 AM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,890 employees as of December 31, 2025. The number of employees increased by 90 or 3.21% compared to the previous year.
Employees
2,890
Change (1Y)
90
Growth (1Y)
3.21%
Revenue / Employee
$1,535,878
Profits / Employee
$10,191
Market Cap
15.29B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,890 | 90 | 3.21% |
| Dec 31, 2024 | 2,800 | 0 | - |
| Dec 31, 2023 | 2,800 | 0 | - |
| Dec 31, 2022 | 2,800 | -400 | -12.50% |
| Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Genmab | 3,088 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
JAZZ News
- 13 hours ago - Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 - PRNewsWire
- 4 days ago - Jazz Pharmaceuticals initiated with a Buy at Canaccord - TheFly
- 4 days ago - Jazz Pharmaceuticals initiated with a Buy at Canaccord - TheFly
- 6 days ago - Jazz Pharmaceuticals Proxy statement: Proxy filing - Filings
- 6 days ago - Jazz Pharmaceuticals price target raised to $285 from $265 at Wells Fargo - TheFly
- 7 days ago - Jazz Pharmaceuticals price target raised to $260 from $253 at Barclays - TheFly
- 11 days ago - Jazz Pharmaceuticals price target raised to $270 from $250 at Deutsche Bank - TheFly
- 13 days ago - Jazz Pharmaceuticals price target lowered to $254 from $256 at Truist - TheFly